These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34367072)

  • 21. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Apr; 40(4):317-21. PubMed ID: 25674857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.
    Yadav MP; Raju S; Ballal S; Bal C
    Clin Nucl Med; 2024 Jan; 49(1):e33-e34. PubMed ID: 37976428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging-Guided Use of Combined
    Ashwathanarayana AG; Biswal CK; Sood A; Parihar AS; Kapoor R; Mittal BR
    J Nucl Med Technol; 2017 Dec; 45(4):314-316. PubMed ID: 28798226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
    Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
    Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twins in spirit part IV - [
    Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
    Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma.
    Roll W; Müther M; Sporns PB; Zinnhardt B; Suero Molina E; Seifert R; Schäfers M; Weckesser M; Stegger L; Beule AG; Stummer W; Rahbar K
    World Neurosurg; 2020 Nov; 143():e391-e399. PubMed ID: 32745642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.
    Pacak K; Taieb D; Lin FI; Jha A
    J Clin Endocrinol Metab; 2024 Aug; 109(9):2366-2388. PubMed ID: 38652045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
    Satapathy S; Mittal BR; Bhansali A
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide receptor radionuclide therapy with (177)Lu DOTATATE in a case of recurrent carotid body paraganglioma with spinal metastases.
    Gupta SK; Singla S; Karunanithi S; Damle N; Bal C
    Clin Nucl Med; 2014 May; 39(5):440-1. PubMed ID: 24217545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 38. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
    Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.